1110641-65-0

Basic information

• Product Name: 1-chloro-5-methyl-3-phenylhex-5-en-3-ol
• Synonyms: 1-chloro-5-methyl-3-phenylhex-5-en-3-ol
• CAS NO: 1110641-65-0
• Molecular Weight: 224.73
• Mol File: 1110641-65-0.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-chloro-5-methyl-3-phenylhex-5-en-3-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-chloro-5-methyl-3-phenylhex-5-en-3-ol(1110641-65-0)
• EPA Substance Registry System: 1-chloro-5-methyl-3-phenylhex-5-en-3-ol(1110641-65-0)

Safety Data

• Hazardous Substances Data: 1110641-65-0(Hazardous Substances Data)

Upstream product

• 936-59-4 3-chloropropiophenone 
• 563-47-3 3-Chloro-2-methylpropene 
• 5674-01-1 2-methylallylmagnesium chloride 
• 3756-30-7 1-iodo-2-methyl-2-propene 
• 1398647-62-5 5,5-dimethyl-2-(2-methylallyl)-1,3,2-dioxaborinane 
• 1433220-26-8 B-2-(2-methylallyl)-1,3,2-dioxaborinane 

Downstream Products

• 1110641-66-1 (S)-3-[(S)-1-(4-bromo-phenyl)-ethyl]-6-(2-methyl-allyl)-6-phenyl-perhydro-1,3-oxazin-2-one 
• 1110641-67-2 (R)-3-[(S)-1-(4-bromo-phenyl)-ethyl]-6-(2-methyl-allyl)-6-phenyl-perhydro-1,3-oxazin-2-one 
• 1114563-27-7 1-((S)-1-(4-bromophenyl)ethylamino)-5-methyl-3-phenylhex-5-en-3-ol 
• 1254223-36-3 3-[(S)-1-(4-bromo-2-methyl-phenyl)-ethyl]-(R)-6-(2-methyl-allyl)-6-phenyl-[1,3]oxazinan-2-one 
• 1428476-67-8 (R)-tert-butyl 4-(6-(2-methylallyl)-2-oxo-6-phenyl-1,3-oxazinan-3-yl)piperidine-1-carboxylate 
• 1262298-33-8 6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-(2-(1-phenyl-1H-1,2,3-triazol-4-yl)propan-2-yl)-1,3-oxazinan-2-one 
• 1262298-52-1 6-((2-methyloxiran-2-yl)methyl)-6-phenyl-3-(2-(1-phenyl-1H-1,2,3-triazol-4-yl)propan-2-yl)-1,3-oxazinan-2-one 
• 1262298-51-0 methyl 3-hydroxy-5-methyl-3-phenylhex-5-enyl(2-(1-phenyl-1H-1,2,3-triazol-4-yl)propan-2-yl)carbamate 
• 1262298-32-7 6-(2-methylallyl)-6-phenyl-3-(2-(1-phenyl-1H-1,2,3-triazol-4-yl)propan-2-yl)-1,3-oxazinan-2-one 
• 1262298-30-5 3-(4-(4-fluorophenyl)-2-methylbut-3-yn-2-yl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one 
• 1262298-50-9 3-(4-(4-fluorophenyl)-2-methylbut-3-yn-2-yl)-6-((2-methyloxiran-2-yl)methyl)-6-phenyl-1,3-oxazinan-2-one 
• 1262298-29-2 3-(4-(4-fluorophenyl)-2-methylbut-3-yn-2-yl)-6-(2-methylallyl)-6-phenyl-1,3-oxazinan-2-one 
• 1262298-49-6 methyl 4-(4-fluorophenyl)-2-methylbut-3-yn-2-yl(3-hydroxy-5-methyl-3-phenylhex-5-enyl)carbamate 
• 1262298-47-4 methyl 3-hydroxy-5-methyl-3-phenylhex-5-enyl(2-methylbut-3-yn-2-yl)carbamate 

Relevant articles and documents

Solvent-free methallylboration of ketones accelerated by tert-alcohols

A solvent- and metal-free process has been developed for the direct methallylboration of ketones employing the stable B-methallylborinane 1, which was accelerated by tertiary alcohols. In the presence of 2.0 equiv of readily available tertiary alcohols such as tert-amyl alcohol, the methallylation products were prepared at room temperature in excellent yields. The salient features of the described process include simple operation, high efficiency, and mild reaction conditions.

CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE

This invention relates to substitued 1, 3-oxazin-2-one compounds of the Formula (I), (II), (IIA), (IIB), (IIC), (II D), (IIE), (III), (III A), (III B), (IV), (IV A), (IV B), (IV C), (IV D), (V), (V A), (V B), (VI), (VI A), (VI B), (VII), (VII A), (VII B), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.

CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1

This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.